Melbourne, June 17, 2026, 03:10 AEST
- CSL traded at A$106.25 late Tuesday, up 0.68%. The stock is up 8.52% for the week. Intelligent Investor
- S&P/ASX 200 edged just higher to 8,917.70 after the RBA held its rate at 4.35%. Business Recorder
- CSL reports FY26 results on August 18. The company plans to provide its next impairments update then.
CSL Limited was last at A$106.25, up A$0.72 or 0.68% late Tuesday, trading between A$104.74 and A$106.70. Shares have bounced 15.19% from the June 3 low, but the stock is still 60.94% below its 52-week high at A$272.00. Traders described the session as tentative rebound buying, not a real change in sentiment. Intelligent Investor
ASX stocks hardly moved, with a few names ticking up. The S&P/ASX 200 ended higher by just 3.7 points at 8,917.70 after the Reserve Bank of Australia left rates steady at 4.35%. S&P Global CSL could benefit if the index keeps firm and money shifts to large caps. Still, there are questions hanging over earnings, assets, and management’s decisions.
CSL shares traded without any new operating info. The latest ASX filings since June are a securities cessation on June 9, a director interest on June 5, and a change in substantial holdings recorded on June 3. No fresh trading update came through. Intelligent Investor Investors are still looking back to May, when interim CEO Gordon Naylor said, “Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise.” CSL has cut the FY26 outlook to around US$15.2 billion in revenue, and US$3.1 billion NPATA, based on constant currency and excluding amortisation and major one-offs.
CSL’s bear scenario looks simple. The company said it expects a total of US$5 billion in extra non-cash pre-tax impairments across FY26 and FY27, mostly from CSL Vifor intangibles, with the rest from plant, property and equipment. CSL will write down assets that no longer match their previous values. There’s also a warning about a US$300 million revenue drop as U.S. immunoglobulin inventory returns to normal levels. In China, albumin revenues get cut by another US$200 million, and there’s about US$150 million in headwinds linked to the Middle East conflict, HEMGENIX, and more pressure in the iron market.
Some bulls argue CSL’s setbacks are already baked in. Google Finance shows 3 Buy calls, 8 Hold, no Sells, and the consensus 12-month price target sits at A$136.09, above the current share price. The lowest target is A$100.00. Google On filings, CSL is flagged as risky rather than simply cheap. Investors looking at the stock are taking a view on plasma and vaccine steadiness, but there are headline risks—impairments, FY26 outlook, CEO transition, and progress on the turnaround plan. Next big update comes with the August 18 FY26 result, when management is set to brief on earnings, impairments, and any turnaround progress.
